RARE DISEASERESEARCH ATLAS

ORPHA:90797

Partial androgen insensitivity syndrome

low confidenceDisorder

Also known as: PAIS · Partial androgen resistance syndrome

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

3,367

Trials

0

Interventional, condition-specific

Researchers

1,147

Distinct authors in sample

Gene link

AR

Strong

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A difference of sex development (DSD) distinct from complete AIS (CAIS) characterized by the presence of abnormal genital development in a 46,XY individual with normal testis development and partial responsiveness to age-appropriate levels of androgens.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (9)

Reifenstein syndrome · Reifenstein syndrome, partial · androgen insensitivity, partial · androgen insensitivity, partial, with or without breast cancer · androgen insensitivity, partial, with or without breast cancer, X-linked recessive · familial incomplete Male pseudohermaphroditism, type 1 · pais · partial androgen resistance syndrome · pseudohermaphroditism, incomplete male, type I

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedPresent

    Strong — AR

  2. LiteraturePresent

    3,367 matched papers (2,350 in last 10 years) Source

  3. Phenotype characterisedPresent

    37 HPO annotations (e.g. Micropenis; Gynecomastia; Infertility) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPartial

    None under the specific name; 1 for broader category androgen insensitivity syndrome

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (AR).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

37

Associated phenotypes · MONDO:0010720

  • Micropenis
  • Gynecomastia
  • Infertility
  • Cryptorchidism
  • Azoospermia

Showing 5 of 37 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

3,367

3,367 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

3,367 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

2,350 in the last 10 years · low confidence

Phrase hits: 1,736 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,147

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Guerra-Junior G5 papers · 2025

    Interdisciplinary Group for Study of Sex Determination and Differentiation (GIEDDS), School of Medicine, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.

    Papers in Europe PMC
  2. 02
    Holterhus PM5 papers · 2026

    Pediatric Endocrinology and Diabetology, University Hospital of Schleswig-Holstein, Kiel, Germany.

    Papers in Europe PMC
  3. 03
    Liu Y5 papers · 2025

    Department of Paediatrics, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, People's Republic of China.

    Papers in Europe PMC
  4. 04
    Chen Y4 papers · 2026

    Department of Paediatrics, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, People's Republic of China.

    Papers in Europe PMC
  5. 05
    Guaragna-Filho G4 papers · 2023

    Interdisciplinary Group for Study of Sex Determination and Differentiation (GIEDDS), Growth and Development Laboratory, Center for Investigation in Pediatrics (CIPED), School of Medicine, State University of Campinas (UNICAMP),R. Tessalia Vieira de Camargo, 126, Campinas, São Paulo 13083-887, Brazil.

    Papers in Europe PMC
  6. 06
    Wang X4 papers · 2026

    Ultrasound Department, Tongji Hospital, Tongji University School of Medicine, Shanghai, 200065, China.

    Papers in Europe PMC
  7. 07
    Zhang Y4 papers · 2026

    Guangdong Provincial Key Laboratory of Synthetic Genomics, Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, P.R. China.

    Papers in Europe PMC
  8. 08
    Ahmed SF3 papers · 2025

    Office for Rare Conditions, University of Glasgow, Glasgow, UK.

    Papers in Europe PMC
  9. 09
    Bryce J3 papers · 2025

    Office for Rare Conditions, University of Glasgow, Glasgow, UK.

    Papers in Europe PMC
  10. 10
    Hiort O3 papers · 2025

    Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University of Lübeck, Lübeck, Germany.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 1 trial are registered for androgen insensitivity syndrome, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

1 interventional trial matched androgen insensitivity syndrome, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: androgen insensitivity syndrome

1

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (1)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Partial androgen insensitivity syndrome — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

Directly listed under NPRD Group 1.

Group 1 — one-time curative treatment

Up to ₹50 lakh per patient

Financial support for treatment at notified Centres of Excellence (figures evolved from the original ₹20 lakh Group-1 ceiling).

Policy figures change. Verify current MoHFW / CoE guidance before relying on any amount. Verify

Centres of Excellence (15)
  • All India Institute of Medical Sciences (AIIMS)New Delhi, Delhi
  • Maulana Azad Medical CollegeNew Delhi, Delhi
  • Sanjay Gandhi Post Graduate Institute of Medical SciencesLucknow, Uttar Pradesh
  • Post Graduate Institute of Medical Education and Research (PGIMER)Chandigarh, Chandigarh
  • Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical SciencesHyderabad, Telangana
  • King Edward Memorial HospitalMumbai, Maharashtra
  • Institute of Post-Graduate Medical Education and Research (IPGMER)Kolkata, West Bengal
  • Centre for Human Genetics with Indira Gandhi HospitalBengaluru, Karnataka
  • Institute of Child Health and Hospital for Children (ICH & HC)Chennai, Tamil Nadu
  • All India Institute of Medical Sciences (AIIMS)Jodhpur, Rajasthan
  • Sree Avittam Thirunal Hospital (SAT), Government Medical CollegeThiruvananthapuram, Kerala
  • All India Institute of Medical Sciences (AIIMS)Bhopal, Madhya Pradesh
  • Regional Institute of Medical Sciences (RIMS)Imphal, Manipur
  • All India Institute of Medical Sciences (AIIMS)Patna, Bihar
  • Assam Medical College & HospitalDibrugarh, Assam

Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Partial androgen insensitivity syndrome" OR "Partial androgen resistance syndrome" OR "Reifenstein syndrome" OR "Reifenstein syndrome, partial" OR "androgen insensitivity, partial" OR "androgen insensitivity, partial, with or without breast cancer" OR "androgen insensitivity, partial, with or without breast cancer, X-linked recessive" OR "familial incomplete Male pseudohermaphroditism, type 1" OR "pseudohermaphroditism, incomplete male, type I") OR (MESH:"Lubs syndrome") OR ("AR syndrome" OR "AR-related")

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Lubs syndrome

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Partial androgen insensitivity syndrome" OR "Partial androgen resistance syndrome" OR "Reifenstein syndrome" OR "Reifenstein syndrome, partial" OR "androgen insensitivity, partial" OR "androgen insensitivity, partial, with or without breast cancer" OR "androgen insensitivity, partial, with or without breast cancer, X-linked recessive" OR "familial incomplete Male pseudohermaphroditism, type 1" OR "pseudohermaphroditism, incomplete male, type I" OR "Lubs syndrome"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"androgen insensitivity syndrome"

Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: PAIS

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (3367) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T03:56:02.518Z